These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37471259)

  • 21. Best Practices in the Development and Validation of Physiologically Based Biopharmaceutics Modeling. A Workshop Summary Report.
    Parrott N; Suarez-Sharp S; Kesisoglou F; Pathak SM; Good D; Wagner C; Dallmann A; Mullin J; Patel N; Riedmaier AE; Mitra A; Raines K; Butler J; Kakhi M; Li M; Zhao Y; Tsakalozou E; Flanagan T; Dressman J; Pepin X
    J Pharm Sci; 2021 Feb; 110(2):584-593. PubMed ID: 33058891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
    Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
    AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls: A Workshop Summary Report.
    Pepin XJH; Parrott N; Dressman J; Delvadia P; Mitra A; Zhang X; Babiskin A; Kolhatkar V; Suarez-Sharp S
    J Pharm Sci; 2021 Feb; 110(2):555-566. PubMed ID: 32380182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of Physiologically Based Biopharmaceutics Modeling (PBBM) in Regulatory Perspective: Application to Supersede f2, Enabling Biowaivers & Creation of Dissolution Safe Space.
    Bhattiprolu AK; Kollipara S; Ahmed T; Boddu R; Chachad S
    J Pharm Sci; 2022 Dec; 111(12):3397-3410. PubMed ID: 36096285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologically Based Biopharmaceutics Model for Selumetinib Food Effect Investigation and Capsule Dissolution Safe Space - Part I: Adults.
    Pepin XJH; Hammarberg M; Mattinson A; Moir A
    Pharm Res; 2023 Feb; 40(2):387-403. PubMed ID: 36002614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Best Practices for Integration of Dissolution Data into Physiologically Based Biopharmaceutics Models (PBBM): A Biopharmaceutics Modeling Scientist Perspective.
    Kollipara S; Bhattiprolu AK; Boddu R; Ahmed T; Chachad S
    AAPS PharmSciTech; 2023 Feb; 24(2):59. PubMed ID: 36759492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies.
    Tistaert C; Heimbach T; Xia B; Parrott N; Samant TS; Kesisoglou F
    J Pharm Sci; 2019 Jan; 108(1):592-602. PubMed ID: 29906472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products.
    Ibarra M; Valiante C; Sopeña P; Schiavo A; Lorier M; Vázquez M; Fagiolino P
    Eur J Pharm Sci; 2018 Jun; 118():176-182. PubMed ID: 29605455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.
    Guimarães M; Vertzoni M; Fotaki N
    AAPS J; 2022 Jan; 24(1):27. PubMed ID: 35013803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
    Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
    Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modelling Based Approaches to Support Generic Drug Regulatory Submissions-Practical Considerations and Case Studies.
    Karnati P; Murthy A; Gundeti M; Ahmed T
    AAPS J; 2023 Jun; 25(4):63. PubMed ID: 37353655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration.
    O'Dwyer PJ; Box KJ; Dressman J; Griffin BT; Henze LJ; Litou C; Pentafragka C; Statelova M; Vertzoni M; Reppas C
    J Pharm Pharmacol; 2021 Mar; 73(4):437-446. PubMed ID: 33793836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.
    Lin W; Chen Y; Unadkat JD; Zhang X; Wu D; Heimbach T
    Pharm Res; 2022 Aug; 39(8):1701-1731. PubMed ID: 35552967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting bioequivalence and developing dissolution bioequivalence safe space in vitro for warfarin using a Physiologically-Based pharmacokinetic absorption model.
    Cheng ZZ; Hu X; Li YL; Zhang L
    Eur J Pharm Biopharm; 2023 Oct; 191():12-25. PubMed ID: 37567396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies.
    Mitra A; Parrott N; Miller N; Lloyd R; Tistaert C; Heimbach T; Ji Y; Kesisoglou F
    J Pharm Sci; 2020 Mar; 109(3):1380-1394. PubMed ID: 31778721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro-In vivo Relationship and Bioequivalence Prediction for Modified-Release Capsules Based on a PBPK Absorption Model.
    Jereb R; Opara J; Legen I; Petek B; Grabnar-Peklar D
    AAPS PharmSciTech; 2019 Dec; 21(1):18. PubMed ID: 31820131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating the bioequivalence of metronidazole tablets and analyzing the effect of
    Zhang S; Fang M; Zhang Q; Li X; Zhang T
    Drug Dev Ind Pharm; 2019 Oct; 45(10):1646-1653. PubMed ID: 31342807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
    Loisios-Konstantinidis I; Dressman J
    Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.